[HTML][HTML] Current trend in antiviral therapy for chronic hepatitis B
RN Chien, YF Liaw - Viruses, 2022 - mdpi.com
Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …
[HTML][HTML] Viral hepatitis: Past, present, and future
MA Odenwald, S Paul - World Journal of Gastroenterology, 2022 - ncbi.nlm.nih.gov
Each hepatitis virus—Hepatitis A, B, C, D, E, and G—poses a distinct scenario to the patient
and clinician alike. Since the discovery of each virus, extensive knowledge regarding …
and clinician alike. Since the discovery of each virus, extensive knowledge regarding …
[HTML][HTML] EASL clinical practice guidelines: management of chronic hepatitis B virus infection
European Association For The Study Of The Liver - Journal of hepatology, 2012 - Elsevier
Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …
for therapy of the resultant disease is continuously improving. New data have become …
[图书][B] The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the …
Organisation mondiale de la santé. Comité d'experts … - 2015 - books.google.com
This report presents the recommendations of the WHO Expert Committee responsible for
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
YF Liaw, JH Kao, T Piratvisuth, HLY Chan… - Hepatology …, 2012 - Springer
Large volume of new data on the natural history and treatment of chronic hepatitis B virus
(HBV) infection have become available since 2008. These include further studies in …
(HBV) infection have become available since 2008. These include further studies in …
[图书][B] Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15
World Health Organization - 2015 - books.google.com
These are the first World Health Organization (WHO) guidelines for the prevention care and
treatment of persons living with CHB infection and complement similar recent published …
treatment of persons living with CHB infection and complement similar recent published …
[HTML][HTML] 核苷(酸) 类似物经治的慢性乙型肝炎患者低病毒血症的研究现状
鲁凤民， 封波， 郑素军， 蒋素贞， 杨瑞锋， 福军亮， 纪冬… - 临床肝胆病杂志, 2021 - lcgdbzz.org
临床上广泛使用的一线抗HBV 药物核苷(酸) 类似物(NAs) 可有效地抑制HBV DNA 复制,
显著减缓慢性乙型肝炎(CHB) 患者的疾病进展, 减少包括肝衰竭和肝癌在内的终末期肝病的发生 …
显著减缓慢性乙型肝炎(CHB) 患者的疾病进展, 减少包括肝衰竭和肝癌在内的终末期肝病的发生 …
核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理
陈成伟， 陈从新， 陈士俊， 陈永平， 成军， 程明亮… - 实用肝脏病杂志, 2013 - cqvip.com
在核苷和核苷酸类药物(NAs) 治疗慢性乙型肝炎过程中, 耐药是一个极为重要的问题.
与未发生耐药的患者比较, 耐药不仅可导致疾病进一步进展, 并可增加发生肝功能失代偿和肝 …
与未发生耐药的患者比较, 耐药不仅可导致疾病进一步进展, 并可增加发生肝功能失代偿和肝 …
Long-term continuous entecavir therapy in nucleos (t) ide-naïve chronic hepatitis B patients
BACKGROUND & AIMS: We determined the antiviral potency and viral resistance rate after
4years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection …
4years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection …
Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels
OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT),
hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related …
hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related …